versione pdf - Sistema Nazionale Linee Guida

Iperplasia prostatica benigna217 Hudson PB, Boake R, Trachtenberg J, RomasNA, Rosenblatt S, Narayan P, et al. Efficacy offinasteride is maintained in patients with benignprostatic hyperplasia treated for 5 years. TheNorth American Finasteride Study Group. Urology1999;53:690-5.218 Lowe FC, McConnell JD, Hudson PB, Romas NA,Boake R, Lieber M, et al, for the FinasterideStudy Group. Long-term 6-year experience withfinasteride in patients with benign prostatichyperplasia. Urology 2003;61:791-6.219 Lepor H, Williford WO, Barry MJ, Brawer MK,Dixon CM, Gormley G, et al. The efficacy of terazosin,finasteride, or both in benign prostatichyperplasia. Veteran Affairs Cooperative StudiesBenign Prostatic Hyperplasia Study Group. NEngl J Med 1996;335:533-9.220 Edwards JE, Moore RA. Finasteride in the treatmentof clinical benign prostatic hyperplasia: asystematic review of randomised trials. BMC Urol2002;2:14.221 Abrams P, Schafer W, Tammela TL, Barrett DM,Hedlund H, Rollema HJ, et al. Improvement ofpressure flow parameters with finasteride isgreater in men with large prostates. FinasterideUrodynamics Study Group. J Urol 1999;161:1513-7.222 Roehrborn CG, Bruskewitz R, Nickel GC, GlickmanS, Cox C, Anderson R, et al. Urinary retentionin patients with BPH treated with finasterideor placebo over 4 years. Characterization ofpatients and ultimate outcomes.The PLESS StudyGroup. Eur Urol 2000;37:528-36.223 Andersen JT, Nickel JC, Marshall VR, SchulmanCC, Boyle P. Finasteride significantly reducesacute urinary retention and need for surgery inpatients with symptomatic benign prostatichyperplasia. Urology 1997;49:839-45.224 Oesterling JE, Roy J, Agha A, Shown T, KrarupT, Johansen T, et al. Biologic variability ofprostate-specific antigen and its usefulness as amarker for prostate cancer: effects of finasteride.Finasteride PSA Study Group. Urology 1998;51(4A suppl):58-63.225 Andriole GL, Guess HA, Epstein JI, Wise H, KadmonD, Crawford ED, et al. Treatment with finasteridepreserves usefulness of prostate-specificantigen in the detection of prostate cancer: resultsof a randomized, double-blind, placebo-controlledclinical trial. PLESS Study Group. ProscarLong-term Efficacy and Safety Study. Urology1998;52:195-201.226 Evans HC, Goa KL. Dutasteride. Drugs Aging2003;20:905-16.227 Roehrborn CG, Boyle P, Nickel JC, Hoefner K,Andriole G, on behalf of the ARIA3001,ARIA3002, and ARIA3003 study investigators.Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) inmen with benign prostatic hyperplasia. Urology2002;60:434-41.228 O’Leary MP, Roehrborn C, Andriole G, Nickel C,Boyle P, Hofner K. Improvements in benign prostatichyperplasia-specific quality of life withdutasteride, the novel dual 5alpha-reductaseinhibitor. BJU Int 2003;92:262-6.229 Wessels H, Roy J, Bannow J, Grayhack J, MatsumotoAM, Tenover L, et al, for the PLESS StudyGroup. Incidence and severity of sexual adverseexperiences in finasteride and placebo-treatedmen with benign prostatic hyperplasia. Urology2003;61:579-84.230 Thompson IM, Goodman PJ, Tangen CM, ScottLucia M, Miller GJ, Ford LG, et al. The influenceof finasteride on the development of prostatecancer. N Engl J Med 2003;349:215-24.231 Andriole GL, Kirby R. Safety and tolerability ofthe dual 5-alpha-reductase inhibitor dutasteridein the treatment of benign prostatic hyperplasia.Eur Urol 2003;44:82-8.232 Lowe FC, Dreikorn K, Borkowski A, BraeckmanJ, Denis L, Ferrari P, et al. Review of recent placebo-controlledtrials utilizing phytotherapeuticagents for treatment of BPH. Prostate 1998;37:187-93.233 Feifer AH, Fleshner NE, Klotz L. Analytical accuracyand reliability of commonly used nutritionalsupplements in prostate disease. J Urol2002;168:150-4.234 Wilt T, Ishani A, Mac Donald R. Serenoa repensfor benign prostatic hyperplasia. Cochrane DatabaseSyst Rev 2002;(3):CD001423.235 Boyle P, Robertson C, Lowe F, Roehrborn C.Meta-analysis of clinical trials of Permixon in thetreatment of symptomatic benign prostatic hyperplasia.Urology 2000;55:533-9.236 Wilt T, Ishani A, Mac Donald R, Rutks I, Stark G.Pygeum africanum for benign prostatic hyperplasia.Cochrane Database Syst Rev2002;(1):CD001044.237 Debruyne F, Koch G, Boyle P, Da Silva FC,Gillenwater JG, Hamdy FC, et al. Comparisonof a phytotherapeutic agent (Permixon) with analpha-blocker (Tamsulosin) in the treatment ofbenign prostatic hyperplasia: a 1-year randomizedinternational study. Eur Urol 2002;41:497-506.238 Glemain P, Coulange C, Billebaud T, Gattegno B,Muszynski R, Loeb G, Groupe de l’essai OCOS.Tamsulosin with or without Serenoa repens inbenign prostatic hyperplasia: the OCOS trial.Prog Urol 2002;12:395-403.239 Denis L, Pagano F, Nonis A, Robertson C,Romano P, Boyle P. Double-blind, placebo-controlledtrial to assess the efficacy and tolerabilityof mepartricin in the treatment of BPH. Prostate1998;37:246-52.240 Granados EA. Flutamide, an alternative forpatients with benign prostatic hyperplasia (BPH)that cannot be treated with surgery. Arch EspUrol 1998;51:675-9.241 Puyol Pallas M, Gomez Parada J. Treatment ofacute urine retention caused by benign prostatichypertrophy with an LH-RH agonist (Goserelin).Actas Urol Esp 1995;19:118-22.242 Eri LM, Tveter KJ. Safety, side effects andpatient acceptance of the luteinizing hormonereleasing hormone agonist leuprolide in treat-44Bibliografia essenziale